Page 3 of 6

AN76.1-2 | Introduction to embryology — Part 2

Phylogeny, Ontogeny, and Evolutionary Developmental Biology

The NMC competency AN76.2 requires explanation of four specific terms: phylogeny, ontogeny, trimester, and viability.

Figure: Phylogeny, Ontogeny, and Evolutionary Developmental Biology

Phylogeny (from Greek phylon = 'race/tribe' + genesis = 'origin') refers to the evolutionary history and diversification of a species or group of organisms. It traces the ancestral relationships between species over millions of years, typically represented as a branching diagram called a phylogenetic tree or cladogram. In the context of embryology, phylogeny is important because of the relationship between evolutionary history and developmental processes.

Ontogeny (from Greek ontos = 'being' + genesis = 'origin') refers to the developmental history of an individual organism from fertilisation to death. It encompasses all the stages of human life described above — pre-embryonic, embryonic, foetal, neonatal, infantile, childhood, adolescent, and adult stages.

The relationship between phylogeny and ontogeny has fascinated biologists for centuries. Ernst Haeckel (1834-1919) proposed the biogenetic law: 'ontogeny recapitulates phylogeny' — the idea that an embryo passes through stages resembling the adult forms of its evolutionary ancestors. For example, the human embryo develops pharyngeal (branchial) arches that resemble the gill arches of fish. However, Haeckel's formulation was an oversimplification and is now considered largely incorrect in its strict form. The human embryo does not pass through a 'fish stage' or a 'reptile stage'. What is correct is that embryos of related species show greater similarity to each other than the adult forms do (von Baer's law) and that structures derived from common evolutionary origins (homologous structures) develop through similar embryological pathways. This is encapsulated in the modern field of evolutionary developmental biology (evo-devo), which studies how changes in developmental genes and regulatory networks drive evolutionary change.

Practical examples of phylogenetic-ontogenetic relationships in human embryology include: (1) Pharyngeal arches — these structures in the human embryo are homologous to the gill arches of fish. In humans, they give rise to structures of the face, jaw, ear, and neck rather than gills. The first pharyngeal arch gives rise to the maxilla, mandible, malleus, and incus; the second arch to the stapes, styloid process, and facial expression muscles; the third arch to the hyoid bone; the fourth and sixth arches to laryngeal cartilages. Pharyngeal grooves (clefts) correspond to fish gill slits but only the first persists as the external acoustic meatus. (2) Pronephros, mesonephros, and metanephros — human kidney development recapitulates the evolutionary sequence from pronephros (functional in lampreys) to mesonephros (functional in fish and amphibians) to metanephros (the definitive mammalian kidney). The pronephros appears and degenerates in the human embryo; the mesonephros functions briefly as an interim kidney before the metanephros develops. (3) Tail regression — the human embryo has a prominent tail during weeks 4-6, which normally regresses. Persistence results in a vestigial tail (caudal appendage), a rare congenital anomaly. (4) Lanugo — the fine hair covering the foetus is homologous to the fur of other mammals and is shed before or shortly after birth.

Recapitulation in clinical practice: Understanding phylogenetic relationships helps explain certain congenital anomalies. A branchial fistula (persistence of a pharyngeal groove and pouch communication) reflects incomplete closure of a structure homologous to a fish gill slit. A cervical rib (present in ~0.5% of people) reflects persistence of a rib on the seventh cervical vertebra — mammals typically have ribs only on thoracic vertebrae, but ancestral reptiles had ribs on all vertebrae. An atavistic feature is the reappearance of a character present in ancestors but typically absent in the species.

Trimesters, Viability, and Clinical Applications

Trimester refers to the clinical division of pregnancy into three periods of approximately 13 weeks each, based on gestational age (from the last menstrual period).

Figure: Trimesters, Viability, and Clinical Applications

First trimester (Weeks 1-12 gestational age / Weeks 1-10 post-fertilisation): This encompasses the entire pre-embryonic and embryonic periods plus the early foetal period. All major organogenesis occurs during this trimester, making it the period of greatest susceptibility to teratogens. Common first-trimester complications include ectopic pregnancy (implantation outside the uterus, most commonly in the fallopian tube — incidence approximately 1-2% of pregnancies, higher in India due to high rates of pelvic inflammatory disease), threatened and spontaneous abortion (miscarriage), hyperemesis gravidarum, and molar pregnancy. Prenatal screening in the first trimester includes: combined screening (nuchal translucency measurement by ultrasound + maternal serum PAPP-A and free beta-hCG at 11-13 weeks) for chromosomal aneuploidies, and non-invasive prenatal testing (NIPT — cell-free foetal DNA in maternal blood, available from 10 weeks, with sensitivity >99% for trisomy 21).

Second trimester (Weeks 13-26 gestational age): This is characterised by rapid foetal growth, the mother feeling foetal movements (quickening, typically at 18-20 weeks in primigravidae, 16-18 weeks in multigravidae), and progressive maturation of organ systems. The anomaly scan (detailed ultrasound examination) at 18-20 weeks is a critical screening tool for structural malformations. Amniocentesis (needle aspiration of amniotic fluid for foetal karyotyping and biochemical testing) is typically performed at 15-18 weeks. Complications include cervical incompetence (painless cervical dilatation and preterm delivery), gestational diabetes mellitus (screening at 24-28 weeks with oral glucose tolerance test), and pre-eclampsia (hypertension + proteinuria after 20 weeks).

Third trimester (Weeks 27-40 gestational age): The foetus gains weight rapidly, the lungs mature (surfactant production reaches adequate levels by approximately 34-36 weeks), and the foetus assumes the typical vertex (head-down) presentation for delivery. Complications include preterm labour, placenta praevia (low-lying placenta covering the cervical os), placental abruption, foetal growth restriction, and eclampsia. Foetal lung maturity can be assessed by amniocentesis measuring the lecithin/sphingomyelin (L/S) ratio (>2:1 indicates maturity) and phosphatidylglycerol levels.

Viability refers to the ability of a foetus to survive outside the uterus. This is a concept that has evolved dramatically with advances in neonatal intensive care. The current international consensus places the lower limit of viability at approximately 22-24 weeks gestational age (20-22 weeks post-fertilisation) and a weight of approximately 500 grams. However, survival at these extreme gestations is low (10-30% at 23 weeks, 30-50% at 24 weeks in well-resourced NICUs) and associated with high rates of significant morbidity including bronchopulmonary dysplasia, intraventricular haemorrhage, necrotising enterocolitis, retinopathy of prematurity, and long-term neurodevelopmental disability.

In India, the legal definition of viability has important implications. The Medical Termination of Pregnancy (MTP) Act, 2021 permits termination up to 20 weeks gestational age by a single registered medical practitioner, and up to 24 weeks for certain categories of women (survivors of rape, minors, those with foetal malformations) by two registered medical practitioners. Beyond 24 weeks, termination is only permitted by a Medical Board for substantial foetal abnormalities. The Registration of Births and Deaths Act requires registration of any birth (live or still) after 28 weeks of gestation. A stillbirth is defined as a foetus born without signs of life after 28 weeks (WHO definition uses 22 weeks or 500g, but India uses 28 weeks).

The concept of viability also intersects with the understanding of periviability — the gestational age range (22-25 weeks) where survival is possible but uncertain, and where clinical decisions about resuscitation involve complex ethical considerations. In India, most district hospitals and many state medical college hospitals lack the level IV NICU facilities required for survival at extreme prematurity, making the practical limit of viability higher (26-28 weeks) than in tertiary referral centres.

Teratology and critical periods provide the practical application of embryological timing. A teratogen is any agent that can cause a structural or functional abnormality in the developing embryo or foetus. Major categories include: drugs (thalidomide, isotretinoin, valproic acid, warfarin, methotrexate, alcohol, lithium, phenytoin, ACE inhibitors in 2nd/3rd trimester), infections (TORCH — Toxoplasma, Others [syphilis, varicella, parvovirus B19], Rubella, Cytomegalovirus, Herpes simplex; and Zika virus), radiation (>5 rads/50 mGy — particularly during weeks 2-15), metabolic (uncontrolled maternal diabetes, phenylketonuria), and mechanical (oligohydramnios causing Potter sequence — pulmonary hypoplasia, limb compression deformities, facial compression). The critical period for each organ is the time during which its cells are actively proliferating and differentiating — teratogenic exposure during this window causes specific malformations of that organ, while the same exposure outside the window has no effect on that organ (though it may affect other organs in their own critical periods).

Teratogenesis: Principles, Indian Context, and Prevention

The principles of teratogenesis were formalised by James G. Wilson (1973) into six general principles that remain foundational. (1) Susceptibility depends on genotype: the same teratogen may cause different effects in different species, strains, or individuals due to genetic differences in metabolism, receptor binding, and repair mechanisms. This is why animal testing does not always predict human teratogenicity (thalidomide was safe in rats but devastating in humans). (2) Susceptibility varies with developmental stage: the pre-embryonic period shows the all-or-none response; the embryonic period is the time of maximum susceptibility to structural malformations; the foetal period is susceptible to growth restriction and functional deficits. (3) Teratogenic agents act in specific ways (mechanisms): these include cell death (apoptosis or necrosis), altered cell proliferation, impaired cellular migration, disrupted cell-cell interactions, reduced biosynthesis of essential molecules, and mechanical disruption. (4) The final manifestations of abnormal development are: malformation (intrinsic defect in morphogenesis — e.g., cleft palate), disruption (breakdown of a previously normal structure — e.g., amniotic band sequence), deformation (abnormal form or position due to mechanical forces — e.g., clubfoot from oligohydramnios), and dysplasia (abnormal organisation of cells into tissues — e.g., skeletal dysplasias). (5) Access to the developing embryo depends on the nature of the agent: route of administration, placental transfer, maternal metabolism, and dose all affect whether a teratogen reaches the embryo in sufficient concentration. (6) Dose-response relationship: increasing dose increases the severity and frequency of abnormalities. There is typically a threshold dose below which no teratogenic effect occurs (except for some agents like alcohol, where no safe threshold has been established).

Figure: Teratogenesis: Principles, Indian Context, and Prevention

Teratogens of particular relevance in India include: (1) Alcohol — foetal alcohol spectrum disorder (FASD) is underdiagnosed in India, where alcohol consumption during pregnancy is common in certain communities and tribal populations. FASD includes foetal alcohol syndrome (FAS — growth restriction, microcephaly, smooth philtrum, thin vermilion, short palpebral fissures, intellectual disability, cardiac defects) and less severe manifestations. There is no established safe level of alcohol consumption during pregnancy. (2) Antiepileptic drugs — India has a large population of women with epilepsy of reproductive age. Valproic acid is particularly teratogenic (neural tube defects in 1-2% of exposed pregnancies, cardiac defects, craniofacial anomalies, and neurodevelopmental effects). The shift toward safer alternatives (levetiracetam, lamotrigine) is an important clinical consideration. (3) Maternal diabetes — with India's high diabetes prevalence, diabetic embryopathy is a significant concern. Poorly controlled pregestational diabetes (particularly during weeks 3-8) increases the risk of cardiac defects (3-4x), neural tube defects (2-3x), sacral agenesis/caudal regression syndrome (200-400x — highly specific for diabetic embryopathy), and other malformations. Periconceptional glycaemic control (HbA1c <6.5%) dramatically reduces these risks. (4) Infections — rubella, though preventable by vaccination, remains endemic in parts of India; congenital rubella syndrome (cataracts, cardiac defects, deafness) occurs when maternal rubella infection occurs in the first 12 weeks. The National Immunisation Schedule now includes rubella vaccination (MR vaccine at 9 months and 16-24 months). Congenital syphilis is also a persistent problem in India, particularly in underserved populations. (5) Radiation — unnecessary diagnostic radiation during early pregnancy remains a concern in Indian healthcare settings where pregnancy testing before radiological procedures is not universally practised.

Prevention of congenital anomalies in the Indian context involves: periconceptional folic acid supplementation (400 μg daily, 4-5 mg for high-risk women), rubella vaccination, preconceptional diabetic control, avoidance of teratogenic medications, antenatal screening (combined first-trimester screening, anomaly scan), and genetic counselling for high-risk families. The Government of India's National Programme for Prevention and Management of Birth Defects aims to reduce the burden of congenital anomalies through improved screening, early intervention, and management at district hospital level.